Peptides on the Evidence Spectrum: From Semaglutide to BPC-157

So a patient hands me a screenshot — six peptides, an injection schedule, claims about tendon healing and cellular repair. My honest reaction is I have no idea where to start.

That's the right place to start, actually. The word peptide tells you nothing about evidence grade. It's a chemistry term — a chain of amino acids. Insulin is a peptide. BPC-157 is a peptide. That's where the similarity ends.

So how do I sort them quickly in a consultation?

Three tiers. First: FDA-approved with guideline support — semaglutide, tesamorelin, approved indications only. Second: investigational, meaning human trials exist but no approval. Third: research chemicals — injected widely, zero published controlled trials in humans.

Where does BPC-157 sit?

Tier three. The tendon and gut healing data is rodent work only. Mechanistic, not clinical. There is no human trial with a clinical endpoint. That's not a soft caveat — it means we genuinely don't know what it does in people.

And tesamorelin? I see that one marketed pretty freely.

Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy. ENDOCRINE Society guidelines support that indication. Outside it — general visceral fat reduction in other populations — you're off-label with modest trial data, no cardiovascular endpoint trials. Tier two at best for that use.

What about semaglutide? That's obviously tier one.

For type 2 diabetes and obesity, yes — SUSTAIN and STEP trials, cardiovascular outcomes data from SELECT. That's guideline-level evidence from tens of thousands of patients. But the same molecule sold as a compounded injectable from an unverified source is a different regulatory and safety question entirely.

That's the part that worries me most practically — the supply chain. What do I actually tell that patient?

You tell them the vial's contents are unverified. No independent lot testing, no manufacturing oversight. The FDA has issued alerts on compounded semaglutide specifically. That's not a theoretical concern — it's a documented purity and concentration problem.

So even for a molecule with excellent evidence, the channel matters.

Exactly. Evidence grade and source integrity are separate axes. You can have a well-evidenced molecule in a bad vial.

What do I actually do when a patient is already using one of the tier-three products and mentions it casually?

Document it, don't dismiss it. Ask what they're using, from where, at what dose. Note it affects your clinical picture — unexplained labs, symptoms. And be honest: we don't have safety data in humans, so you can't reassure them, and you can't scare them with something you can't support.

The one thing you'd want me to hold onto from this?

Peptide is a chemistry descriptor, not an evidence grade. Every time a patient says that word, your first move is to name the specific molecule and place it on the tier. Everything else follows from that.